Inactive Instrument

INSTEM

INS

GB00B3TQCK30

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

January 26, 2022 at 12:30 pm IST

Instem plc provides revenue guidance for the year ended 31 December 2021. For the year, the company expects Total Revenue of GBP 46.1 million against GBP 28.2 million reported a year ago.

Latest news about INSTEM

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline	25/01	CI
Instem Delists from London Bourse's AIM After Merger with ArchiMed	21/11	MT
France's Archimed Completes Acquisition of UK's Instem	20/11	MT
Instem plc Announces Board Resignations	20/11	CI
ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.	20/11	CI
Instem acquisition by Ichor sanctioned by UK court	17/11	AN
UK Court Clears Archimed’s Takeover of Instem	16/11	MT
Actual Experience appoints administrators	07/11	AN
Instem's Acquisition by Archimed's Ichor Management Granted UK Regulatory Nod	07/11	MT
Instem shareholders back motions relating to Archimed offer	04/11	AN
Instem, Archimed’s Ichor Management Agree Acquisition Deal Price	30/23/30	MT
Instem Postpones Court, General Meetings for Archimed Bid as New Suitors Surface	20/23/20	MT
Instem adjourns meeting after disclosing further approaches	18/23/18	AN
Instem shares fall back as Archimed says offer is final	13/23/13	AN
AIM WINNERS & LOSERS: TomCo raises funds; Instem bid "final"	13/23/13	AN
Archimed's Ichor Management Says GBP203 Million Cash Offer for Instem is Final	13/23/13	MT
Instem's second-largest shareholder opposes deal with PE firm Archimed	28/23/28	RE
Instem swings to loss in first half but posts revenue growth	15/23/15	AN
Instem plc Reports Earnings Results for the Half Year Ended June 30, 2023	15/23/15	CI
Fears for the Chinese economy weigh on the FTSE 100	31/23/31
FTSE 100 Ends Higher, Helped by Hopes of US Rate Pause	30/23/30	DJ
UK Net Mortgage Approvals Fall As Interest Rates Remain High	30/23/30	DJ
FTSE 100 outperforms European peers	30/23/30	AN
AIM WINNERS & LOSERS: Instem soars on GBP200 million takeover	30/23/30	AN
Prudential outperforms; Instem jumps on takeover	30/23/30	AN

Instem plc is a United Kingdom-based company that is a provider of information technology (IT) solutions to the global life sciences market. The Company operates through four segments: Study Management, Regulatory Solutions, In Silico Solutions and Clinical Trial Acceleration. Study Management Solutions offers software that enables organizations to collect, review, manage and report discovery and preclinical data. Regulatory Solutions provides software, outsourced services and consulting for managing, storing, sharing, submitting and maintaining information compliant with agency regulations. The Company's In Silico Solutions enable researchers to generate scientific insights through the identification, extraction and analysis of information. Clinical Trials Acceleration Solutions offers technology solutions and consulting services to facilitate data integration, statistics, analytics and insights for companies of any size or stage of clinical trial analysis.

Sector

More about the company

INSTEM

Equities

INS

GB00B3TQCK30

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

Latest news about INSTEM

Chart INSTEM

Company Profile